Trulive Medical Double-Crowned at Future Healthcare 100 Summit 2026, Recognized on Two Prestigious Innovation and Investment Rankings
Trulive
Structural Heart Disease Device Developer
Recently, the "2026 Future Healthcare and Pharmaceutical 100 Strong Conference," jointly organized by VB Data in collaboration with 142 innovative healthcare and pharmaceutical companies, investment firms, industrial parks, and medical institutions, grandly opened in Shanghai. As the annual benchmark event in the healthcare industry, this conference focuses on cutting-edge innovation directions and core popular sectors, providing an in-depth analysis of the industry landscape and future trends. The conference also released the authoritative annual value list on-site. Trulive Medical once again stood out with its hardcore innovation capabilities in the cardiovascular interventional device field, solid commercialization achievements, and outstanding long-term investment value.Successfully selected into the "Top 50 Most Investment-Worthy Enterprises in China's Healthcare Industry" and the "Top 100 List of Innovative Devices and Intelligent Manufacturing"The dual honors fully demonstrate the company's strong development potential.
The selection system for the Future Healthcare 100 Strong ranking is rigorous and professional, undergoing multiple rounds of stringent screening. It comprehensively evaluates companies from various dimensions such as innovative R&D, product pipelines, China-produced alternatives, team building, and global layout. This benchmark selection is highly credible, recognized by the industry, and holds significant reference value in the Chinese healthcare sector.
This dual-listing crowning is a high recognition from the industry, capital, and market of Trulive's innovation strength, development potential, and industrial contribution. Deeply cultivating the high-end cardiovascular intervention device track, Trulive always focuses on clinical needs, concentrates on the frontier direction of cardiovascular interventional treatment, continuously breaks through key core technologies, and builds a comprehensive product matrix; at the same time, it accelerates product clinical transformation and commercial landing, steadily advancing the overseas layout of domestically produced high-end devices, assisting in the continuous upgrading of diagnostic and treatment technologies in the cardiovascular field.
In the future, Trulive will take this honor as motivation to continue深耕innovative device赛道, increase R&D investment, strengthen technological innovation and clinical value output, empower national health with high-quality domestically produced innovative devices, and contribute to the high-quality development of China's healthcare industry.
-End-
Trulive
Jiangsu Trulive Medtech Co., Ltd. focuses on the field of cardiovascular diseases, which have extremely high mortality and disability rates and remain a gap in the domestically-produced market. Its business comprehensively covers multiple interventional treatment areas such as heart valves, peripherals, and coronary arteries. It is a platform enterprise that takes the lead in providing a one-stop innovative solution for blood flow management globally. With strong research and development capabilities and a senior, full-fledged operational team, Trulive Medtech has developed high-quality, proprietary medical devices with independent intellectual property rights and complete solutions, filling the gap in China's high-end cardiovascular interventional medical device market. This provides more advanced and diverse treatment options for Chinese doctors and patients. Meanwhile, based in China and expanding globally, Trulive Medtech continuously upgrades through technological innovation and development, accelerating the expansion of its global commercial network. In many niche markets within the cardiovascular intervention field that have long been monopolized by imported products, Trulive Medtech offers "Chinese solutions" and contributes "Chinese wisdom."
Scan the QR code to follow us
Business Cooperation | 0513-68302888
Email Address | qiqi.he@trulive.cn